Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
Top Cited Papers
Open Access
- 10 May 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 119 (19), 4391-4394
- https://doi.org/10.1182/blood-2011-11-390930
Abstract
Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AKeywords
This publication has 22 references indexed in Scilit:
- Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk ScoreMayo Clinic Proceedings, 2011
- Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2011
- Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportLeukemia & Lymphoma, 2010
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationBlood, 2007
- High-Dose Melphalan versus Melphalan plus Dexamethasone for AL AmyloidosisThe New England Journal of Medicine, 2007
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisBlood, 2006
- Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic AmyloidosisJournal of Clinical Oncology, 2004
- Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationBlood, 2004
- Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosisAmyloid, 2003
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineThe New England Journal of Medicine, 1997